Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06222944
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-25
First Post:
2024-01-16
Brief Title:
Anlotinib TQB2450 PD-L1 Inhibitor and Albumin-bound Paclitaxel Regimens in the Treatment of GCGEJA
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
A Multi-Center Multi-Cohort Study of the Efficacy and Safety of Anlotinib TQB2450 and Albumin-bound Paclitaxel in CLDN182-regimen-failed Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to assess the efficacy and safety of a combination therapy consisting of Anlotinib TQB2450 a PD-L1 inhibitor and Albumin-bound Paclitaxel regimens in patients with advanced gastric cancer GC or gastroesophageal junction adenocarcinoma GEJA who have failed the previous treatment with Claudin182 CLDN182-related regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None